Autolus Therapeutics Sells Unregistered Equity, Raises Capital

TL;DR

**Autolus just sold new shares privately, likely diluting existing stock but boosting cash.**

AI Summary

Autolus Therapeutics plc entered into a material definitive agreement on February 6, 2024, involving an unregistered sale of equity securities. This indicates the company raised capital by selling shares directly to investors without a public offering. For current or prospective shareholders, this means potential dilution of existing shares, as more shares are now in circulation, which could impact the stock price.

Why It Matters

This filing signals that Autolus Therapeutics has secured funding, which is crucial for its operations, but it also means existing shareholders might own a smaller percentage of the company.

Risk Assessment

Risk Level: medium — The unregistered sale of equity securities can lead to dilution for existing shareholders, potentially impacting share value, but it also provides necessary capital for the company's operations.

Analyst Insight

An investor should investigate the terms of the material definitive agreement and the specifics of the unregistered equity sale to understand the extent of dilution and the intended use of proceeds, as this could impact future stock performance.

Key Players & Entities

• Autolus Therapeutics plc (company) — the registrant filing the 8-K
• February 6, 2024 (date) — date of the earliest event reported

Forward-Looking Statements

• Autolus Therapeutics plc will use the capital raised from the unregistered equity sale to fund ongoing research and development. (Autolus Therapeutics plc) — medium confidence, target: 2025-02-06

FAQ

From the Filing

0001193125-24-027393.txt : 20240208 0001193125-24-027393.hdr.sgml : 20240208 20240208060600 ACCESSION NUMBER: 0001193125-24-027393 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 20 CONFORMED PERIOD OF REPORT: 20240206 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240208 DATE AS OF CHANGE: 20240208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 24606708 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 d782679d8k.htm 8-K 8-K 00-0000000 false 0001730463 0001730463 2024-02-06 2024-02-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024     Autolus Therapeutics plc (Exact name of registrant as specified in its Charter)       England and Wales   001-38547   Not applicable (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices) (Zip Code) (44) 20 3829 6230 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, par value $0.000042 per share   AUTL   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01 Entry into a Material Definitive Agreement License and Option Agreement On February 6, 2024 (the “ Execution Date ”), Autolus Therapeutics plc (the “ registrant ”) and the registrant’s wholly owned subsidiaries, Autolus Limited and Autolus Holdings (UK) Limited (together, with the regis